Zongertinib’s Accelerated FDA Approval Marks First Oral Drug for HER2-Mutated NSCLC

The FDA has granted accelerated approval to zongertinib (Hernexeos), a groundbreaking oral medication for adults with unresectable or metastatic nonsquamous non-small cell lung cancer (NSCLC). This approval is a significant milestone, as zongertinib is the first oral drug of its kind specifically for patients whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations and who have received prior systemic therapy. The drug’s approval was supported by compelling safety and efficacy data from the phase 1a/1b Beamion LUNG-1 trial.

A New Treatment for an Aggressive Disease

NSCLC is the most common type of lung cancer, accounting for roughly 80% to 85% of all cases. HER2 mutations are found in approximately 2% of NSCLC diagnoses and are associated with a more aggressive and progressive form of the disease. Zongertinib is a tyrosine kinase inhibitor (TKI) that is designed to address this specific mutation. Its mechanism of action involves irreversibly and selectively blocking HER2 activity while minimizing unwanted side effects by sparing EGFR inhibition.

The FDA’s decision was based on positive findings from the first-in-human, open-label Beamion LUNG-1 trial, which evaluated zongertinib as a monotherapy in patients with advanced or metastatic nonsquamous NSCLC with HER2 TKD mutations. The trial’s primary outcomes were objective response rate (ORR) and duration of response (DOR).

Clinically Meaningful Results from Beamion LUNG-1

The trial data demonstrated clinically meaningful and durable responses in patients, particularly in those who had not previously received a HER2-targeted therapy. The results were analyzed in two key patient groups:

Patients with prior platinum-based chemotherapy but no prior HER2-targeted TKI or antibody-drug conjugate (ADC): In this group of 71 patients, the ORR was approximately 75%. Furthermore, 58% of these patients achieved a DOR of at least 6 months.
Patients with prior platinum-based chemotherapy and a HER2-targeted ADC: Among the 34 patients in this group, the ORR was approximately 44%. A DOR of at least 6 months was maintained by 27% of these patients.

Dosing and Administration

The recommended dose of zongertinib is weight-based. Patients weighing less than 90 kg should take 120 mg orally once daily, while those weighing 90 kg or more should take 180 mg once daily. The medication can be taken with or without food and should be continued until the disease progresses or the patient experiences unacceptable toxicity.

The accelerated approval of zongertinib offers a vital and much-needed new treatment option for a specific subset of patients with HER2-mutated NSCLC, providing hope for improved outcomes in a challenging disease.